Zentalis Pharma Prices $80.5 Million Share Offering at $3.50

Corporate Action
โดย RTTNews·US·Read original
Summary · why it matters

Zentalis Pharmaceuticals has priced a public offering of 23 million shares at $3.50 per share, expecting total gross proceeds of $80.5 million. The clinical-stage oncology company plans to use the net proceeds to fund clinical trials, preclinical studies, regulatory filings, and manufacturing. TD Cowen, Guggenheim Securities, and Oppenheimer & Co. are acting as joint bookrunners, with H.C. Wainwright & Co. as passive bookrunner and Rodman & Renshaw LLC as manager. Zentalis develops treatments for ovarian cancer and multiple tumour types, with lead investigational drug Azenosertib in development for ovarian cancer. The stock closed Thursday at $4.15, down 3.26%, and fell a further 9.16% to $3.77 in overnight trading.

Impact on stocks 2

Biotech & Genomic Medicine▼ · 1 stocks
Financials▲ · 1 stocks

Off-coverage companies 3

Guggenheim SecuritiesPrivate± Mixed
relevance

H.C. Wainwright & Co.Private± Mixed
relevance

Rodman & Renshaw LLCPrivate± Mixed
relevance

© 2026 MarketDXNews